Harnessing the power of the BioXp® system
Given the COVID-19 global healthcare emergency, accelerating the pace of innovation and developing tools to combat the spread of COVID-19 is paramount. The scientific community is operating at its creative best to identify and advance solutions for prevention, detection, and treatment. The BioXp® system is the ideal platform to enable researchers around the world to rapidly synthesize SARS-CoV-2 genome parts, making them readily available for developing vaccines, diagnostics, and therapeutics.
In this application note, we describe the on-demand production of the entire genome of SARS-CoV-2. Genome parts were designed and synthesized using the BioXp® system. We also describe the joining of these parts to assemble the full-length genome of SARS-CoV-2 as a bacterial artificial chromosome (BAC) in E. coli. Given the number of genome variants of SARS-CoV-2 that have been identified thus far, it may become imperative to incorporate them into the vaccine, therapeutic, and diagnostic development pipelines quickly. The BioXp® system accelerates this pipeline by enabling rapid synthesis of up to 32 individual variant genome parts in a single overnight run of the instrument.
